NASDAQ:VRAY - Viewray Stock Price, Forecast & News

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Viewray Inc (NASDAQ:VRAY) released its earnings results on Tuesday, November, 12th. The company reported ($0.21) EPS for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.06. The company earned $20.90 million during the quarter, compared to analysts' expectations of $20.66 million. Viewray had a negative return on equity of 75.41% and a negative net margin of 110.61%. The firm's revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.39) EPS. View Viewray's Earnings History.

Viewray is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Viewray.

Viewray issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$80-95 million, compared to the consensus revenue estimate of $$89.28 million.

9 Wall Street analysts have issued twelve-month price targets for Viewray's stock. Their forecasts range from $5.00 to $9.00. On average, they expect Viewray's share price to reach $6.44 in the next year. This suggests a possible upside of 60.3% from the stock's current price. View Analyst Price Targets for Viewray.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.

News stories about VRAY stock have trended extremely negative recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Viewray earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Viewray.

Some companies that are related to Viewray include InMode (INMD), Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), Reshape Lifesciences (RSLS), Zynex (ZYXI), BioLife Solutions (BLFS), Stereotaxis (STXS), Semler Scientific (SMLR), BioSig Technologies (BSGM), Edap Tms (EDAP), Rockwell Medical (RMTI), Fonar (FONR) and Second Sight Medical Products (EYES).

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Sarepta Therapeutics (SRPT), Square (SQ), Advanced Micro Devices (AMD), Amarin (AMRN), Amicus Therapeutics (FOLD), Iovance Biotherapeutics (IOVA) and Pieris Pharmaceuticals (PIRS).

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Viewray's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (1.56%), State Street Corp (1.37%), Rhenman & Partners Asset Management AB (0.65%), Kahn Brothers Group Inc. DE (0.35%), Essex Investment Management Co. LLC (0.15%) and Russell Investments Group Ltd. (0.13%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray.

VRAY stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Rhenman & Partners Asset Management AB, Essex Investment Management Co. LLC, Perkins Capital Management Inc., Pennsylvania Trust Co, Stephens Inc. AR and Squarepoint Ops LLC. View Insider Buying and Selling for Viewray.

VRAY stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Kahn Brothers Group Inc. DE, Investor AB, Parallel Advisors LLC, Virtu Financial LLC, Raymond James Trust N.A., Allworth Financial LP and Russell Investments Group Ltd.. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray.

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VRAY stock can currently be purchased for approximately $4.02.

Viewray has a market capitalization of $399.63 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. View Additional Information About Viewray.

The official website for Viewray is http://www.viewray.com/.

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]